{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:36:01Z","timestamp":1788478561813,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.heliyon.2024.e30608","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T22:43:41Z","timestamp":1714689821000},"page":"e30608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Kikuchi disease: A case report about Sintilimab-induced Kikuchi histiocytic necrotizing lymphadenitis and literature review"],"prefix":"10.1016","volume":"10","author":[{"given":"Chunxiao","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglan","family":"Tuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.heliyon.2024.e30608_bib1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1097\/MS9.0000000000000372","article-title":"Kikuchi-Fujimoto disease in a 20-year-old female: a case report","volume":"85","author":"Gurung","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.heliyon.2024.e30608_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.heliyon.2024.e30608_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.769124","article-title":"Research progress of anti-PD-1\/PD-L1 immunotherapy related mechanisms and predictive biomarkers in NSCLC","volume":"12","author":"Bie","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30608_bib4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2024.e30608_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: a promising anti-tumor PD-1 antibody","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30608_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40364-020-00250-z","article-title":"Recent updates on Sintilimab in solid tumor immunotherapy","volume":"8","author":"Liu","year":"2020","journal-title":"Biomark. Res."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e30608_bib7","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.heliyon.2024.e30608_bib8","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30608_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040924","article-title":"PD-L1-PD-1 pathway in the pathophysiology of multiple myeloma","volume":"12","author":"Tamura","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30608_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040663","article-title":"Recent advancements in the mechanisms underlying resistance to PD-1\/PD-L1 blockade immunotherapy","volume":"13","author":"Yuan","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30608_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12890-023-02417-4","article-title":"A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer","volume":"23","author":"Hu","year":"2023","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30608_bib12","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e30608_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082533","article-title":"Role of immune checkpoint inhibitors in gastrointestinal malignancies","volume":"9","author":"Mazloom","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.heliyon.2024.e30608_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820948773","article-title":"Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers","volume":"13","author":"Eso","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30608_bib15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30608_bib16","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1245\/s10434-018-07131-8","article-title":"Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery","volume":"26","author":"Nagakawa","year":"2019","journal-title":"Ann. Surg Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30608_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00423-019-01754-5","article-title":"Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study","volume":"404","author":"Kurahara","year":"2019","journal-title":"Langenbeck's Arch. Surg."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30608_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30608_bib19","first-page":"375","article-title":"Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma","volume":"70","author":"Grossberg","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"10242","key":"10.1016\/j.heliyon.2024.e30608_bib20","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e30608_bib21","article-title":"Advancements in systemic therapy for pancreatic cancer","volume":"43","author":"Brown","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30608_bib22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4251\/wjgo.v15.i4.571","article-title":"Recent advances in targeted therapy for pancreatic adenocarcinoma","volume":"15","author":"Fang","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.heliyon.2024.e30608_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.01.031","article-title":"Trials and tribulations of pancreatic cancer immunotherapy","volume":"504","author":"Principe","year":"2021","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30608_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12964-021-00789-w","article-title":"Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review","volume":"19","author":"Li","year":"2021","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.heliyon.2024.e30608_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2023.04.012","article-title":"Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort","volume":"188","author":"Ta\u00efeb","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30608_bib26","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.21873\/anticanres.14242","article-title":"Adjuvant postoperative CD40 agonist and PD-1 antagonist combination therapy in syngeneic tongue cancer mouse model","volume":"40","author":"Ahn","year":"2020","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30608_bib27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","article-title":"Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma","volume":"21","author":"Gibney","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.heliyon.2024.e30608_bib28","article-title":"Postoperative adjuvant therapy for resectable esophageal cancer: a protocol of a systematic review and meta-analysis","volume":"98","author":"Chai","year":"2019","journal-title":"Medicine (Baltim.)"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30608_bib29","first-page":"93","article-title":"\u80f0\u817a\u5b9e\u6027\u5047\u4e73\u5934\u72b6\u7624\u8bca\u65ad\u4e0e\u6cbb\u7597\u73b0\u72b6\u548c\u8fdb\u5c55[J]PLASM of the pancreas","volume":"29","author":"\u5218\u5f81\u6d9b","year":"2016","journal-title":"Arq Bras Cir Dig"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30608_bib52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1590\/0102-6720201600020007","article-title":"Solid pseudopapillary neoplasm of the pancreas","volume":"29","author":"Carlotto","year":"2016","journal-title":"Arq Bras Cir Dig"},{"issue":"49","key":"10.1016\/j.heliyon.2024.e30608_bib31","article-title":"Aggressiveness of solid pseudopapillary neoplasm of the pancreas: a literature review and meta-analysis","volume":"97","author":"Hao","year":"2018","journal-title":"Medicine (Baltim.)"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30608_bib32","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1177\/0300060513488516","article-title":"Retrospective analysis of 102 cases of solid pseudopapillary neoplasm of the pancreas in China","volume":"41","author":"Wang","year":"2013","journal-title":"J. Int. Med. Res."},{"issue":"49","key":"10.1016\/j.heliyon.2024.e30608_bib33","article-title":"Aggressiveness of solid pseudopapillary neoplasm of the pancreas: a literature review and meta-analysis","volume":"97","author":"Hao","year":"2018","journal-title":"Medicine (Baltim.)"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e30608_bib34","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.3390\/cancers15082216","article-title":"Rare non-neuroendocrine pancreatic tumours","volume":"15","author":"Mormul","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e30608_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108707","article-title":"The efficacy of PD-1\/PD-L1 blockade in cold cancers and future perspectives","volume":"226","author":"Majidpoor","year":"2021","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30608_bib36","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3892\/ol.2023.13974","article-title":"Postoperative pathological complete response in a patient with PD-L1-negative stage IIIB lung squamous cell carcinoma following neoadjuvant tislelizumab treatment combined with chemotherapy: a case report and literature review","volume":"26","author":"Cui","year":"2023","journal-title":"Oncol. Lett."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e30608_bib37","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30608_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30608_bib39","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.5858\/arpa.2018-0219-RA","article-title":"Kikuchi-Fujimoto disease: a review","volume":"142","author":"Perry","year":"2018","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.heliyon.2024.e30608_bib40","series-title":"StatPearls","author":"Masab","year":"2023"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30608_bib41","article-title":"Kikuchi-Fujimoto disease associated with sj\u00f6gren's syndrome: a case report","volume":"5","author":"Al-Allaf","year":"2018","journal-title":"Eur J Case Rep Intern Med"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30608_bib42","article-title":"Systemic lupus erythematosus lymphadenopathy presenting as kikuchi-fujimoto disease in an adolescent","volume":"15","author":"Harrison","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.heliyon.2024.e30608_bib43","article-title":"Kikuchi-Fujimoto disease: a differential for when it is not systemic lupus erythematosus","volume":"2022","author":"Kazmi","year":"2022","journal-title":"Case Rep Rheumatol"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30608_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/biom11070928","article-title":"Clinical and immunological biomarkers for systemic lupus erythematosus","volume":"11","author":"Yu","year":"2021","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30608_bib45","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"European League against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30608_bib46","article-title":"Kikuchi's disease","volume":"140","author":"Aln\u00e6s","year":"2020","journal-title":"Tidsskr. Nor. Laegeforen"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30608_bib47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4103\/0974-777X.145234","article-title":"Kikuchi-fujimoto disease: clinical and laboratory characteristics and outcome","volume":"6","author":"Rakesh","year":"2014","journal-title":"J Glob Infect Dis"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30608_bib48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/0973-029X.64300","article-title":"Kikuchi's disease","volume":"14","author":"Chaitanya","year":"2010","journal-title":"J. Oral Maxillofac. Pathol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30608_bib49","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30608_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30608_bib51","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.20892\/j.issn.2095-3941.2021.0052","article-title":"Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events","volume":"18","author":"Bai","year":"2021","journal-title":"Cancer Biol Med"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024066398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024066398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T01:49:45Z","timestamp":1758678585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024066398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2405844024066398"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30608","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kikuchi disease: A case report about Sintilimab-induced Kikuchi histiocytic necrotizing lymphadenitis and literature review","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30608","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e30608"}}